The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

RDY FINANCIAL STATEMENTS

Dr. Reddy’s Laboratories Ltd ADR — balance sheet, income statement and cash flow trends

RDYDr. Reddy’s Laboratories Ltd ADR

🇺🇸 USA · US · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
0100 B200 B300 B202120222023202420252026

Profit Funnel

Q1 2026 · TTM
Revenue337.1 B INRGross Profit177.8 B INR · 53%Operating Income49.7 B INR · 15%Pre-tax Income54.8 B INR · 16%Net Income42.9 B INR · 13%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue337.1 B INR+3.6%
Gross Profit177.8 B INR-6.6%
Operating Income49.7 B INR-30.8%
EBITDA77.3 B INR-18.8%
Net Income42.9 B INR-24.2%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
RDY3.6%52.7%22.9%12.7%
Industry median7.5%60.6%18.2%4.0%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0200 B400 B202120222023202420252026

Capital Structure

Q1 2026
Total Assets567.9 B
  • Equity369.6 B INR65%
  • Current Liabilities164.2 B INR29%
  • Long-term Liabilities30.7 B INR5%

Key Figures

YoY change
Total Assets567.9 B INR+15.2%
Total Liabilities195 B INR+25.1%
Total Equity369.6 B INR+10.9%
Cash & ST Investments86.1 B INR+48.6%
Total Debt75.8 B INR+62.1%
Net Debt60.7 B INR+89.2%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
RDY1.8020.5%-0.1365.1%
Industry median2.2246.3%1.2445.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
025 B50 B75 B202120222023202420252026

Cash Flow Bridge

Q1 2026 · TTM
020 B40 B56.5 B INROperating-67.2 B INRInvesting10 B INRFinancing-712.2 M INRNet Change

Key Figures

YoY change
Operating Cash Flow56.5 B INR+21.8%
Capital Expenditures32.3 B INR-6.1%
Free Cash Flow24.3 B INR+101.6%
Dividends Paid-6.5 B INR-148.8%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
RDY16.8%7.2%9.6%131.9%
Industry median15.2%11.6%2.5%84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on RDY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. This content is for informational purposes only and is not investment advice.